semaglutide cv outcomes and Cardiovascular in Obesity without Diabetes semaglutide cardiovascular outcomes study news

2008 Oct;126(10):1396-403

Small-molecule oral GLP-1 RAs, such as orforglipron and danuglipron, are in development or early clinical trials

Pica behavior is a validated endpoint to assess the ability of a compound to induce nausea/malaise in non-vomiting species, as mouse, based on the monitoring of non-nutritive (kaolin) food intake, as an index of gastrointestinal discomfort 43,44

The weight loss drugs appear to help in two ways: first by curbing obesity, which is a risk factor for many other health conditions, and second by reducing inflammation, affecting the brains reward signals and impulse control, and improving blood flow